Hologic (NSDQ:HOLX) said it closed the $125 million deal to acquire bioresorbable tissue marker developer Focal Therapeutics yesterday. Aliso Viejo, Calif.-based Focal Therapeutics makes the BioZorb bioresorbable, three-dimensional tissue marker for marking the tumor excision site in lumpectomies. Hologic said it plans to add the BioZorb marker to its breast health product portfolio. The Marlborough, Mass.-based company said […]
Focal Therapeutics
Hologic to buy Focal Therapeutics for $125m
Hologic (NSDQ:HOLX) said today it inked a $125 million deal to acquire bioresorbable tissue marker developer Focal Therapeutics. Aliso Viejo, Calif.-based Focal Therapeutics produces the BioZorb bioresorbable, three-dimensional tissue marker which is intended to improve lumpectomy surgeries by marking the tumor excision site for monitoring and future treatments. Hologic said that it will add the BioZorb marker […]
Focal Therapeutics touts BioZorb breast cancer implant data
Focal Therapeutics today released data from 2 studies of its BioZorb device designed to provide radiographic markings of soft tissue sites. The marker is made up of a bioabsorbable framework holding 6 titanium clips. The framework dissolves over a year in the body, the company said, while the clips stay in place so the surgical […]